The NeurologyLive® MS Disease Spotlight page offers specific updates and coverage on the latest expert conversations and data readouts related to the treatment and management of patients with multiple sclerosis and demyelinating disorders.
July 25th 2024
Tiziana Life Sciences’ intranasal foralumab has shown potential in treating nonactive secondary progressive multiple sclerosis through innovative immune modulation.
Cutting Edge Care in Multiple Sclerosis: Advances in S1P Therapy
July 28th 2021Jessica L. Stulc, MD, MPH, offered an in-depth review of the latest approved therapies in the sphingosine phosphate 1 targeting class of oral medications for MS including ozanimod (Zeposia; BMS) and ponesimod (Ponvory; Janssen).
Biogen and InnoCare Reach Collaboration Agreement for BTK Inhibitor Orelabrutinib
July 18th 2021Orelabrutinib has the potential to inhibit B cell and myeloid cell effector functions in the central nervous system and may provide a clinically meaningful benefit on progression in all forms of MS.
Atrophied Lesion Volume as a Biomarker of Disability in Progressive Multiple Sclerosis
June 29th 2021Robert Zivadinov, MD, PhD, director, Buffalo Neuroimaging Analysis Center, spoke to the findings of a post-hoc analysis of atrophied T2-lesion volume as a biomarker in patients with progressive MS.
MRI in Multiple Sclerosis Guidelines Update: North America, Europe Align on New Recommendations
June 15th 2021These consensus guidelines are significant not only for their key updates to clinical practice but for their representation of a more unified, global approach to diagnosing and monitoring patients with multiple sclerosis.